Navigation Links
Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
Date:9/4/2008

ZURICH, Switzerland, September 4 /PRNewswire/ -- Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug. Initial results are expected in summer 2009. Axentis Pharma acquired all the necessary rights for this formulation from international partners just eight months ago. In addition to these advances, the company has also succeeded in appointing two renowned experts to its Scientific Advisory Board.

Axentis Pharma AG (Switzerland) announced today that all the necessary requirements for a clinical phase IIa trial have been fulfilled. The objective of this trial is to assess the safety and tolerability of an inhalable tobramycin, a well characterised and established drug for the treatment of pulmonary infection in cystic fibrosis patients. The product ARB-CF0223 ­ also known as Fluidosome(R) tobramycin ­ is a liposomal formulation of tobramycin, delivered directly to the site of infection via standard nebulizers. ARB-CF0223 has an improved safety profile and higher efficacy compared to current treatments for infections of the respiratory tract in patients with cystic fibrosis. It can be used in lower doses and also reduces the frequency and severity of side effects for pulmonary infections. The company expects to begin recruiting patients at its four international trial centres by the end of the year.

Dr. Hans Schreier, Chief Scientist of Axentis Pharma on the advances the company has made: "It was only very recently that we obtained all the necessary legal rights including transfer of sponsorship of the EMEA Orphan Designation to further develop our current lead product, Fluidosome(R) tobramycin. How
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
7. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
10. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
11. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Research and Markets  has announced the addition ... report to their offering. The Central ... the largest segments of pharmaceuticals industry. The numbers of CNS ... therapies were unable to meet the market requirements. There has ... disorder, especially over the past two decades. The market for ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... , EMERYVILLE, Calif., Nov. 5 Bionovo, Inc. (Nasdaq: ... focused on the unmet needs in women,s health and ... for the three months ended September 30, 2009. , ... 2009, Bionovo successfully completed a public offering and issued ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be ... Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. ... president of finance and chief financial officer at Amylin Pharmaceuticals, ... of the presentation will be webcast and a recording will ...
Cached Medicine Technology:Bionovo Announces Third Quarter 2009 Highlights and Financial Results 2Bionovo Announces Third Quarter 2009 Highlights and Financial Results 3Bionovo Announces Third Quarter 2009 Highlights and Financial Results 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 5Bionovo Announces Third Quarter 2009 Highlights and Financial Results 6Bionovo Announces Third Quarter 2009 Highlights and Financial Results 7Bionovo Announces Third Quarter 2009 Highlights and Financial Results 8Bionovo Announces Third Quarter 2009 Highlights and Financial Results 9
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... to store, retrieve, organize and analyze biological and ... comprises of the activity of developing software tools ... is not to be confused with biological computation. ... the better understanding of biology can its related ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... September 01, 2014 Pastor Thompson is an ... at Eagle Village. He is a licensed minister through the ... the past twenty years in New Mexico, Colorado and North ... of marriage this year. He also has two beautiful ... B.S. in Pastoral Ministry from Nazarene Bible College, in Colorado ...
(Date:9/1/2014)... 01, 2014 Psychogenic Non-epileptic Seizures (PNES), ... psychological disorder that can have devastating effects on those ... epileptic seizures however, they are not produced by electrical ... It is estimated that the numbers of persons ... multiple sclerosis. , Dr. Lorna Myers, Director ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... key part of health care reform that requires all Americans ... people gaining coverage, but would not dramatically increase the cost ... comes as the U.S. Supreme Court prepares to hear arguments ... key provision of 2010,s Affordable Care Act. According ...
... News) -- Using an autoinjector device to deliver ... effective way to treat status epilepticus, a prolonged type ... report. "This is a very important study for ... French, first vice president of the American Epilepsy Society. ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- How fast you ... help predict your odds for dementia or stroke later in life, ... can be easily performed in a doctor,s office, noted study author ... and her colleagues tested the walking speed, hand grip strength and ...
... Hospitalization for underage drinking is common in the United States, ... total cost for these hospitalizations is about $755 million per ... found geographic and demographic differences in the incidence of alcohol-related ... Journal of Adolescent Health . Of the ...
... may be receiving the highest exposure to nanoparticles of titanium ... than adults, according to a new study. Published in ACS, ... first broadly based information on amounts of the nanomaterial ... and environmental effects in a wide range of consumer ...
... -- About 27 million Americans aged 50 and older have ... hearing aid, a new study finds. However, many people ... insurance, they don,t receive training in integrating hearing aids into ... part of aging and not a major concern, according to ...
Cached Medicine News:Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 2Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 3Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 2Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 3Health News:Can Walking Speed, Hand Grip in Middle Age Predict Dementia Risk? 2Health News:Mayo Clinic: Hospitalization of US underage drinkers common, costs $755 million a year 2Health News:Millions of Americans Have Untreated Hearing Loss: Study 2
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Soft, autoclavable, and without conformer....
Size: Small. 20.50 mm by 22.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: